CClinicalTrials.gg
CompletedNCT06408064Updated Sep 19, 2024

The Effect of Music Therapy as an Adjuvant in the Vital Signs of the Neonate

An interventional study of Music therapy in Neonatal Disease, sponsored by Claudia Aristizábal. Completed at 1 site in Colombia. Open to participants aged 32 Weeks to 40 Weeks. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by Claudia Aristizábal · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
32 Weeks to 40 Weeks
Sex
All
01

Study summary

The admission of a newborn to the neonatal intensive care unit (NICU) represents a potentially harmful sound environment coupled with multiple stressful events. However, a strategy such as music therapy (delivered by a trained music therapist) appears to be a non-invasive, safe, and cost-effective alternative that assists newborns in their physiological self-regulation with a beneficial effect on stabilizing neonatal vital signs, so it can be used as a complementary strategy to medical management. The aim of this study is to determine the effect of live and pre-recorded music therapy on vital sign variables in newborns older than 32 weeks hospitalized in the neonatal intensive care unit of a high-complexity health institution in Colombia.

Read the detailed description

A parallel, controlled randomized clinical trial will be conducted.

Study Population: Newborns older than 32 weeks gestational age at birth hospitalized in the Neonatal Intensive Care Unit of a high-complexity health institution who meet the inclusion criteria.

Outcomes: Heart rate will be primary outcome. Respiratory rate and oxygen saturation will be secondary outcomes. The patient monitor will be utilized to measure the heart rate, respiratory rate, and oxygen saturation.

Standardization of measurements:

First, the trademarks of the medical equipment manufacturers of each of the tools that will be used (vital sign monitor and pulse oximeter) will be verified to ensure that they correspond to the same commercial brand. Since different brands may exhibit variability in standard calibration measurements within the critical range, it is important to verify that the tools are of the same brand. Secondly, it will be verified that each medical tool used has been calibrated within the previous six months, with the date of the last calibration recorded so that the device can be used during the study. Subsequently, the professional in charge of the music company will verify that the guitar to be used during the live music is in tune and suitable for use. A decibel regulator will be employed during the implementation of both pre-recorded and live music, adjusting the volume of the emitted sound. This will ensure that the decibels emitted by each research subject remain within the permitted range of 70 decibel (dB). Vital variables will be recorded at minute 0, from minute 0 to minute 10 continuously, and at 30 minutes after the intervention.

02

Conditions studied

  • Neonatal Disease
03

In context

Infant, Newborn, Diseases

134 studies on the registry are indexed under Infant, Newborn, Diseases; 30 are open to participants now.

This study's enrollment of 45 is below the median of 72 across 81 interventional studies indexed under Infant, Newborn, Diseases.

Browse Infant, Newborn, Diseases studies →

Lead sponsor

Claudia Aristizábal is the lead sponsor of 8 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
32 Weeks to 40 Weeks
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Newborns with gestational age at birth greater than or equal to 32 weeks.
  • Birth weight greater than or equal to 1500 grams.
  • Be at least 72 hours of postnatal age.

Exclusion criteria

Exclusion Criteria:

  • Respiratory disturbances in the last 48 hours such as: Apnea or Brief Resolved Unexplained Events (BRUE), need for invasive mechanical ventilation
  • Hemodynamic alterations in the last 48 hours such as: Hypotension (systolic, diastolic, or mean BP \< P5) or hypertension (systolic, diastolic, or mean BP > P95), bradycardia (HR \< 100/min), shock of any etiology, requirement for volume expanders, infusion of inotropics, vasodilators and/or prostaglandin E1.
  • Neurological alterations such as: Perinatal asphyxia at birth manifested by the need for resuscitation, APGAR \< 3 at 5 minutes and/or ≤ 5 at 10 minutes, and metabolic acidosis in cord gases with a potential of hydrogen (pH) \< 7 and base excess (BE) \< -12, hypoxic-ischemic encephalopathy, seizure syndrome for up to 48 hours after the last clinical event or alteration of the brain pattern, interventricular hemorrhage in preterm infants in the first week of diagnosis.
  • Management with Extracorporeal membrane oxygenation (ECMO) and/or nitric oxide
  • Temperature less than 36.5 C or greater than 37.5 C.
  • Patient under pharmacological sedation or use of beta-blockers.
  • Congenital heart disease, operated on or not.
  • Congenital malformations
  • Surgical emergencies or recovery from a surgical procedure performed within the last 48 hours.
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
45 participants (actual)

Study arms

  • Experimental
    Live music

    It is performed by a music therapist using the guitar as the only musical instrument. Instrumental lullabies are used, selected by the patient's legal guardian.

    Other: Music therapy

  • Experimental
    Pre-recorded music

    Pre-recorded music of the lullaby genre, instrumental type, using a speaker placed inside the patient's incubator.

    Other: Music therapy

  • No intervention
    Control

    There will be no musical intervention.

Interventions

  • OtherMusic therapy

    Music therapy is a non-pharmacological therapeutic intervention that will be implemented through two modalities: live and pre-recorded instrumental lullabies music.The volume control will be conducted within the groups through the use of a decibel regulator, with a maximum volume of 70 dB. During the intervention and for a period of 30 minutes following its conclusion, singing will be prohibited by the music therapist or the parents. Both live and pre-recorded music will be instrumental in nature, lacking any lyrics.

06

What researchers measure

Primary outcomes

  1. Heart rate

    The measurement will be continuously quantified in terms of number of pulsations per minute continuously.

    Time frame: The baseline measurement will be taken before the intervention, and will continue for 30 minutes during the intervention and for a further 30 minutes after the intervention has been completed.

Secondary outcomes

  1. Respiratory rate

    The measurement will be continuously quantified in terms of the number of breaths per minute.

    Time frame: The baseline measurement will be taken before the intervention, and will continue for 30 minutes during the intervention and for a further 30 minutes after the intervention has been completed.

  2. Oxygen saturation

    The measurement will be continuously quantified in terms of proportion per minute.

    Time frame: The baseline measurement will be taken before the intervention, and will continue for 30 minutes during the intervention and for a further 30 minutes after the intervention has been completed.

07

Study locations

1 site
  • Clínica Universitaria Colombia
    Bogotá, Colombia
08

References and documents

Study documents

  • Study protocol · Apr 30, 2024

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No — When the study ends, individual participant data could be shared with the approval of the research ethics committee.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06408064
Lead sponsor
Claudia Aristizábal
Collaborators
Sanitas University
Responsible party
Claudia Aristizábal (Director, Sanitas University) — Sponsor-investigator
First posted
May 9, 2024
Start date
May 3, 2024
Primary completion
Jul 18, 2024
Completion
Jul 18, 2024
Last update
Sep 19, 2024

Study contacts

Johana Benavides, MSc
study director · Unisanitas

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion